curefordepression

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five curefordepression children with asthma with metabisulfite curefordepression intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop curefordepression in the second metabisulfite challenge.6

With no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in Oregon, Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. They were immunoassayed for specific IgE antibodies using a curefordepression chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8

“The high CD4/CD8 curefordepression ratio and suppressed NK cell activity were improved by methyl-B12 curefordepression treatment.” The Japanese researchers state: “We conclude that vitamin B12 acts as an immunomodulator for cellular immunity.”11 B12 was used successfully in the treatment of IgE-mediated skin disorders. The German researchers conclude that B12 (cobalamin) when applied to the skin one or more times per day exhibited “...excellent results in topical treatment of skin disorders and in particular of inflammatory and hyperproliferative skin ailments curefordepression and/or cutaneous manifestations of illness which are immunologic in curefordepression origin, e.g. psoriasis, atopic dermatitis, contact dermatitis, and other eczematous dermatitises...”12 Click here for Allergy medication online curefordepression.